For depression in PD, the risk of combining antidepressants with serotonergic properties and MAO-B inhibitors is the life-threatening serotonin syndrome (Pd Med Collaborative Group et al., 2014; Smith et al., 2015). Here, MAOB is linked to depressive symptom measurement.